We report the case of a nondiabetic man who developed diabetic ketoacidosis associated with high-dose olanzapine. Olanzapine has been associated with diabetic ketoacidosis and also with weight gain, lipid abnormalities, and the development of type 2 diabetes. This case is of interest both because of the sudden onset and because the patient's blood glucose stabilized 1 month after discontinuation of olanzapine, thus allowing insulin therapy to be discontinued. The patient has now been stabilized on ziprasidone with no further abnormalities in blood glucose.
Howes OD, Rifkin L. Diabetic keto-acidotic (DKA) coma following olanzapine initiation in a previously euglycemic women and successful continued therapy with olanzapine. J Psychopharmacol. 2004;18:435-437.
2.
Lindenmayer J, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus. Am J Psychiatry. 1999;156:1471-1471.
3.
Gatta B, Rigalleau V, Gin H. Diabetic ketoacidosis with olanzapine treatment. Diabetes Care. 1999;22:1002-1003.
4.
Ragucci K, Wells B. Olanzapine-induced diabetic ketoacidosis. Ann Pharmacother. 2001;35:1556-1558.
5.
Spivak B, Alamy S, Jarskog L, et al. Ziprasidone alternative for olanzapine-induced hyperglycemia. Am J Psychiatry. 2002;159:1606-1606.
6.
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. J Clin Psychiatry. 2004;65:267-272.
7.
Koller E, Doraiswamy P. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002;22:841-852.
8.
Straker D, Medelowitz A, Karlin L, et al. Near fatal ketoacidosis with olanzapine treatment. Psychosomatics. 2002;43: 339-340.
9.
Torrey EF, Swalwell C. Fatal olanzapine-induced ketoacidosis. Am J Psychiatry. 2003;160:2241-2241.
10.
Avella J, Wetli C, Wilson J, et al. Fatal olanzapine-induced hyperglycemic ketoacidosis. Am J Forens Med Pathol. 2004;25:172-175.
11.
Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry. 2004;161:1709-1711.
12.
Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes and diabetic ketoacidosis associated with atypical antipsychotic: an analysis of 45 published cases. Ann Clin Psychiatry. 2002;14:59-64.
13.
Goff D, Cather C, Evins E, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005;66:183-194.
14.
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
15.
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.
